AN2 Therapeutics, Inc. (NASDAQ: ANTX) has begun a Phase 2 investigator‑initiated study of its oral boron‑based drug epetraborole for pulmonary disease caused by Mycobacterium abscessus complex. The 84‑patient, multicenter, randomized, double‑blind trial is led by Dr. Kevin Winthrop at Oregon Health & Science University; patient screening started in early April and topline data are expected in late 2027.
The study represents a strategic pivot for AN2, which previously focused on a MAC lung disease program that failed to meet primary endpoints. By targeting M. abscessus, the company is addressing a market of 12,000–18,000 U.S. patients who have no approved oral therapies, creating a potential new revenue stream if the drug proves effective.
AN2’s approach relies on its proprietary boron‑chemistry platform and the use of investigator‑initiated trials, a strategy that reflects limited internal resources but strong scientific focus. The company recently completed a $40 million private placement in March 2026, extending its cash runway to 2029 and maintaining a debt‑free balance sheet.
"Individuals living with M. abscessus lung disease face an incredibly difficult treatment journey, and today's milestone reflects our commitment to changing that trajectory," said CEO Eric Easom. "Mycobacterium abscessus remains one of the most challenging pulmonary pathogens, with limited treatment options consisting of prolonged, poorly tolerated, complex, multidrug daily IV regimens. An orally administered, novel investigative agent such as epetraborole, if shown to be safe and effective in humans, has the potential to become a backbone agent in multidrug regimens for the treatment of M. abscessus lung disease. A new therapeutic that could reduce the burden imposed by current treatment options and improve outcomes for patients with this difficult‑to‑treat infection would be welcomed by patients and care providers alike," added Dr. Winthrop.
The initiation of this Phase 2 trial is a significant milestone for AN2, positioning the company to address a critical unmet medical need and potentially reshape the treatment paradigm for M. abscessus lung disease. The study’s outcomes will inform the next steps in the drug’s development and could open a new therapeutic avenue for a patient population with limited options.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.